Story
NHTSA Ends Airbag Defect Inquiry Into 807,000 Honda Odyssey Minivans

Summary
The U.S. auto safety regulator has closed a defect petition for over 800,000 Honda Odyssey vehicles from model years 2011-2017, citing insufficient evidence of a widespread airbag issue to warrant a formal investigation.
The U.S. National Highway Traffic Safety Administration (NHTSA) has closed its review of a defect petition concerning potential inadvertent airbag deployments in approximately 807,000 Honda Odyssey minivans, concluding there is not enough evidence to launch a formal investigation.
Details of the Decision
The decision, announced on Tuesday, affects 806,963 Honda Odyssey vehicles from the 2011 to 2017 model years in the United States. According to the NHTSA, its review of the petition found "insufficient evidence of a defect trend to warrant a formal probe."
This action concludes the preliminary inquiry and means the agency will not compel Honda to issue a recall over this specific concern. For the automaker, the closure avoids a potentially costly and complex engineering analysis and recall campaign.
Background of the Petition
The petition that triggered the review alleged two primary issues with the vehicles' safety systems. It claimed that airbags could deploy without a sufficiently severe triggering event, such as a crash, while the vehicles were in motion.
AdAdditionally, the petition alleged that the airbag system was recording inaccurate diagnostic information, which could complicate the assessment of any such incidents.
Agency's Findings
In its assessment, the NHTSA analyzed consumer complaints and other submitted reports alleging inadvertent airbag deployments. The agency stated it did not identify a clear pattern or a single factor that linked the reported incidents.
Crucially for vehicle owners, the regulator also noted that it was not aware of any crashes or severe injuries resulting from the alleged deployments. Without a clear defect trend or associated injuries, the agency determined a formal investigation was not justified.
Read next
More on Stocks
Egetis Therapeutics Stock Hits 52-Week High on FDA Approval for Rare Disease Drug
Shares of the Swedish biotech company surged over 13% after its drug, Emcitate, received U.S. Food and Drug Administration approval, becoming the first sanctioned treatment for the rare genetic disorder MCT8 deficiency.

Nvidia CEO's AI Safety Stance Draws Criticism From Pope Leo XIV
Pope Leo XIV has publicly criticized Nvidia CEO Jensen Huang for dismissing risks associated with artificial intelligence, adding a prominent moral voice to the global debate over the technology's regulation.

European Stocks Advance as AI Spending Outlook Boosts Tech Sector
European markets rose on Tuesday, led by a rally in semiconductor stocks after reports on AI startup Anthropic's spending plans offset broader concerns about rising bond yields.

Toyota China Sales Plunge 23% in August Amid EV Shift
The automaker reported its seventh consecutive monthly sales decline in China as high fuel prices accelerate consumer demand for electric vehicles, impacting the company's global performance and stock price.